e-learning
resources
ERJ
2012
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Population-based survival for malignant mesothelioma after introduction of novel chemotherapy
Damhuis Ronald A.M., Schroten Caroline, Burgers Jacobus A.
Source:
Eur Respir J 2012; 40: 185-189
Journal Issue:
July
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Damhuis Ronald A.M., Schroten Caroline, Burgers Jacobus A.. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur Respir J 2012; 40: 185-189
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Asbestosis
Management of solitary fibrous tumours of the pleura: a systematic review and meta-analysis
Diagnosis and staging of malignant pleural mesothelioma
Related content which might interest you:
Long time survival after resection for multiple primary lung cancers. A population-based study
Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology
Year: 2005
Malignant pleural mesothelioma: new treatment modalities
Source: Annual Congress 2005 - Clinical year in review
Year: 2005
A randomised trial of active symptom control (ASC) with or without chemotherapy (CT) in the treatment of patients with malignant pleural mesothelioma. First results of the Medical Research Council/British Thoracic Society MS01 trial
Source: Annual Congress 2007 - Pleural malignancy
Year: 2007
Salvage treatment in patients with recurrent or resistant malignant pleura mesothelioma. A retrospective study from tertiary oncology department
Source: International Congress 2016 – Mesothelioma and malignant pleural disease
Year: 2016
Systemic treatment of malignant mesothelioma
Source: Eur Respir Mon; 2009: 44: 419–434
Year: 2009
Determinants of survival in patients with malignant pleural mesothelioma (MPM) managed at a single institution in Liguria, Italy
Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma
Year: 2018
Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy
Source: Eur Respir J 2012; 39: 1437-1442
Year: 2012
Epidemiology, histology and thoracoscopic findings in malignant pleural mesothelioma (MPM) as second tumour in a single-centre cohort
Source: Annual Congress 2010 - Clinical diagnosis and management of malignant pleural effusions
Year: 2010
Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma
Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma
Year: 2018
Challenges in the management of SCLC Part 2: Extensive disease, prophylaxis/treatment of brain metastases
Source: ERS webinar 2021: Challenges in the management of SCLC Part 2: Extensive disease, prophylaxis/treatment of brain metastases
Year: 2021
Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma?
Source: Eur Respir J 2003; 22: Suppl. 45, 29s
Year: 2003
Regular follow-up after curative resection of nonsmall cell lung cancer: a real benefit for patients?
Source: Eur Respir J 2002; 19: 464-468
Year: 2002
Follow-up and surveillance for lung cancer
Source: Annual Congress 2005 - MP5 - Follow-up and surveillance for lung cancer
Year: 2005
Is there any place for perioperative radiation therapy?
Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts
Year: 2005
Population-based study of synchronous primary malignant lung tumours
Source: Breathe 2008; 4: 368
Year: 2008
Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019
Management of lung cancer screening and incidental findings as well as their integration in existing lung cancer care
Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach
Year: 2019
Clinical and biological prognostic factors in malignant pleural effusion (MPE) secondary to breast cancer
Source: Annual Congress 2005 - What's new in the pleura
Year: 2005
Survival with in-operable non-small cell lung cancer in U.K district general hospital: Is chemotherapy better than active supportive care?
Source: Annual Congress 2010 - Best supportive care and palliation for lung cancer patients
Year: 2010
Prospective population-based study on the survival of patients with lung cancer
Source: Eur Respir J 2002; 19: 1087-1092
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept